Welcome to Medications.com

Abbott Reports 16.1 Percent Sales Growth in Fourth Quarter - Earthtimes

... $74 million, or $0.05 per share, primarily for costs associated with an asset impairment related to the generic introduction of Biaxin XL, $69 million, ...

http://www.earthtimes.org/article... | Posted: Wed Jan 23 08:00:47 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea